Gedeon Richter

Gedeon Richter is a century-old, publicly traded European pharmaceutical company with a strong foundation in generic drugs and a strategic pivot towards innovative therapeutics, particularly in Women's Health. The company is actively expanding its innovative pipeline through internal R&D and strategic acquisitions, such as the Celmatix discovery portfolio, and partnerships, like the recent joint development agreement with Fuji Pharma. With a commercial footprint in over 100 countries and a significant R&D investment, Richter is transitioning from a generics-focused player to an innovation-driven specialty pharma company, as evidenced by recent European Commission approvals for novel products like FYLREVY®.

Integrated small molecule pharmaceutical R&D and manufacturing. Capabilities in medicinal chemistry, pharmacology, and clinical development, augmented by acquired discovery assets in women's health biology.

In generics, Richter competes with global giants like Teva, Sandoz, and Viatris, as well as local players. In innovative Women's Health, it competes with large pharma (e.g., Pfizer, Bayer) and specialty biopharma companies. Its integrated model and regional strength provide a distinct competitive position.